This concept is validated by studies showing that targeting CXCR4 function through neutralizing antibodies inhibited prostate cancer bone metastasis [29], and overexpression of CXCR4 in prostate cancer cells enhanced bone metastasis [30]. Here, CXCR4 is linked to prostate cancer.